Avance Clinical Featured in Fierce Biotech on Intranasal Expertise - Avance Clinical

With the global intranasal drug delivery market estimated to reach up to $71 billion over the next five years, Avance Clinical is seeing an increase in biotech clinical trials targeting this growing…

Fierce Medtech's 2020 Fierce 15

COVID-19 tracker: Omicron variant could cause global surge, WHO says; J&J recipients opt for other boosters

Sick with “Shareholder Value”: US Pharma's Financialized Business Model During the Pandemic

Top Pharma Rep Focus Sales experience B2B Sales Content for Tue.Nov 21, 2023

The Top Line Podcast on Music

Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2 [PeerJ]

H1 adds $38M to series C to build out its healthcare network

Avance Clinical GlobalReady - Avance Clinical

Avance Clinical - Delivering Global Ready Drug Development for Biotechs

Respiratory syncytial virus infection and novel interventions

Nasal-Swab Lung Cancer Test

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications, Journal of Biomedical Science